COSTANTINI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 2.650
EU - Europa 1.361
AS - Asia 218
OC - Oceania 23
AF - Africa 3
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.258
Nazione #
US - Stati Uniti d'America 2.650
UA - Ucraina 292
IT - Italia 255
SE - Svezia 244
IE - Irlanda 179
DE - Germania 138
DK - Danimarca 96
GB - Regno Unito 65
SG - Singapore 62
TR - Turchia 60
FI - Finlandia 50
KR - Corea 49
CN - Cina 34
AU - Australia 23
FR - Francia 23
BE - Belgio 11
IN - India 7
JP - Giappone 4
NL - Olanda 3
CH - Svizzera 2
CI - Costa d'Avorio 2
CO - Colombia 2
RO - Romania 2
TH - Thailandia 2
EU - Europa 1
PL - Polonia 1
TN - Tunisia 1
Totale 4.258
Città #
Chandler 376
Jacksonville 317
Fairfield 247
Dublin 177
Ashburn 149
Wilmington 140
Des Moines 123
Woodbridge 112
Seattle 89
Ann Arbor 85
Boardman 82
New York 78
San Mateo 73
Houston 71
Lawrence 71
Princeton 71
Redmond 58
Cambridge 49
San Diego 40
Centro 38
Rome 23
Marche 21
Beijing 20
Turin 16
London 15
Melbourne 15
Istia D'ombrone 12
Norwalk 12
Brussels 11
Washington 11
Civitanova Marche 9
Los Angeles 9
Porto 9
Chiaravalle 8
Kingscliff 8
Mcallen 6
Charlotte 5
Helsinki 5
Pune 5
Auburn Hills 4
Bristol 4
Castelfiorentino 4
Falls Church 4
Kilburn 4
Weihai 4
Ancona 3
Bologna 3
Hounslow 3
Istanbul 3
Nanjing 3
Napoli 3
Perugia 3
Taranto 3
Torre Annunziata 3
Vallefoglia 3
Abidjan 2
Acton 2
Bangkok 2
Bogotá 2
Boydton 2
Cedar Knolls 2
Frankfurt am Main 2
Hanover 2
Izmir 2
Kingsland 2
Miami 2
Montespertoli 2
New Bedfont 2
Nocera Superiore 2
Nürnberg 2
Prescot 2
Stroudsburg 2
Zurich 2
Amandola 1
Bari 1
Bollengo 1
Caserta 1
Chengdu 1
Chicago 1
Chiswick 1
Falconara Marittima 1
Fremont 1
Ghedi 1
Guangzhou 1
Jesi 1
Lana 1
Macerata 1
Miami Beach 1
Mumbai 1
New Delhi 1
Osimo 1
Ostra 1
Pescara 1
Ponte nelle Alpi 1
Redwood City 1
San Benedetto Del Tronto 1
San Tammaro 1
Stillwater 1
Tappahannock 1
Tunis 1
Totale 2.783
Nome #
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 96
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 94
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 94
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 94
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 91
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 91
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis. 89
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 87
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 80
Effects of cryopreservation on lymphocyte immunophenotype and function 79
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 79
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 78
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 78
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 77
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 75
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 74
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 73
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 72
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. 72
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 71
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 70
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 66
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 66
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 66
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 64
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 63
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 63
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 62
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 61
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 59
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 59
CROI 2013: le ricadute per la pratica clinica. 58
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 58
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 57
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 57
Lo studio fenotipico di linfociti e altre cellule mononucleate. 56
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 56
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 55
Do we still need CD4 T cell count? 55
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 55
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 55
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 55
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 55
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 54
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 54
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 53
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 51
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 50
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 49
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 49
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 49
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 49
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 48
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 48
Il paziente adulto con immunodeficienza. 47
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 47
Polyclonal serum-free light chains elevation in HIV-infected patients. 46
Diagnostica immunologica. 45
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 43
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. 43
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 42
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 42
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 41
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 39
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 39
Infezione da HIV-1. 38
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 36
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 35
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 35
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 34
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 33
L’immunoricostituzione, un paesaggio dai mutevoli confini 32
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 31
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 24
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 24
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 8
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 7
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 2
Totale 4.382
Categoria #
all - tutte 20.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.752


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201910 0 0 0 0 0 0 0 0 0 0 3 7
2019/2020462 10 1 68 6 70 52 63 5 70 13 14 90
2020/20211.058 71 105 129 13 123 44 95 63 126 93 122 74
2021/2022585 37 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024550 105 11 31 85 133 125 18 17 12 13 0 0
Totale 4.382